Litcius/Paper detail

A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations

Takashi Ninomiya, Nobuhisa Ishikawa, Toshiyuki Kozuki, Shoichi Kuyama, Koji Inoue, Toshihide Yokoyama, Nobuhiro Kanaji, Masayuki Yasugi, Takuo Shibayama, Keisuke Aoe, Nobuaki Ochi, Kazunori Fujitaka, Masahiro Kodani, Yutaka Ueda, Kazuhiko Watanabe, Akihiro Bessho, Keisuke Sugimoto, Isao Oze, Katsuyuki Hotta, Katsuyuki Kiura

2023Lung Cancer15 citationsDOI

Topics & Concepts

MedicineAfatinibBevacizumabInternal medicineHazard ratioLung cancerClinical endpointRashOncologyRandomized controlled trialProgression-free survivalConfidence intervalGastroenterologyErlotinibEpidermal growth factor receptorCancerChemotherapyLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesLung Cancer Diagnosis and Treatment
A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations | Litcius